Prevalence+of+Anxiety+Disorders%0d%0a27%0d%0a%0d%0aLifetime+Prevalence+(%25)%0d%0a%0d%0a24+21+18+15+12+9+6+3+0+Any+Anxiety+Disorder+Social+Anxiety+Disorder+PTSD+Generalized+Anxiety+Disorder+Panic+Disorder%0d%0a%0d%0aKessler+et+al.+Arch+Gen+Psychiatry.+1995%3b52%3a1048.+Kessler+et+al.+Arch+Gen+Psychiatry.+1994%3b51%3a8.%0d%0a%0d%0a%0cOutcome+of+Panic+Disorder+at+Long-Term+Follow-up%0d%0aPersistence+of+Panic+attacks+Phobic+avoidance+Functional+impairment+Rate+(%25)+Range+(%25)+46+69+50+17-70+36-82+39-67%0d%0aRoy-Byrne+%26+Cowley%2c+1995%0d%0a%0d%0a%0c%0c%0c%0cPharmacopoeia+for+Anxiety+Disorders%0d%0aAntidepressants%0d%0aSerotonin+Selective+Reuptake+Inhibitors+(SSRIs)+Serotonin-Norepinephrine+Reuptake+Inhibitors+(SNRIs)+Atypical+Antidepressants+Tricyclic+Antidepressants+(TCAs)+Monoamine+Oxidase+Inhibitors+(MAOIs)%0d%0a%0d%0aBenzodiazepines+Other+Agents%0d%0aAzaspirones+Beta+blockers+Anticonvulsants+Other+strategies%0d%0a%0d%0a%0cSerotonin+Selective+Reuptake+Inhibitors%0d%0a%e2%80%a2+Fluoxetine+(Prozac)%2c+20-80+mg%2fd%0d%0a%e2%80%93+Initiate+with+5-10+mg%2fd%0d%0a%0d%0a%e2%80%a2+Sertraline+(Zoloft)%2c+50-200+mg%2fd%0d%0a%e2%80%93+Initiate+with+25-50+mg%2fd%0d%0a%0d%0a%e2%80%a2+Paroxetine+(Paxil)%2c+20-50+mg%2fd%0d%0a%e2%80%93+Initiate+with+10mg%2fd%0d%0a%0d%0a%e2%80%a2+Fluvoxamine+(Luvox)%2c+50-300+mg%2fd%0d%0a%e2%80%93+Initiate+with+25+mg%2fd%0d%0a%0d%0a%e2%80%a2+Citalopram+(Celexa)+-+Initiate+with+10-20+mg%2fd+%e2%80%a2+Start+low+to+minimize+anxiety+Adjunctive+BZD%2c+beta+blocker%0d%0a%0d%0a%0cSerotonin+Selective+Reuptake+Inhibitors+(cont)%0d%0a%e2%80%a2+Typical+SSRI+side+effects%3a%0d%0a%e2%80%93+GI+distress%2c+jitteriness%2c+headaches%2c+sleep+disturbance%2c+sexual+disturbance%0d%0a%0d%0a%e2%80%a2+Clomipramine+(Anafranil)%2c+25-250+mg%2fd%0d%0a%e2%80%93+Initiate+with+25+mg%2fd%0d%0a%0d%0a%e2%80%a2+Efficacy%3a+PDAG%2c+PTSD%2c+SP%2c+OCD%2c+GAD%0d%0a%0d%0a%0cSertraline+In+Comorbid+PTSD+And+Alcoholism%0d%0aPre-treatment+Post-treatment+60+140%0d%0a%0d%0a40+IES+score+20+70+Standard+drinks%2fweek%0d%0a%0d%0a0+IES+Alcohol+use%0d%0a%0d%0a0%0d%0a%0d%0aBrady+et+al.+J+Clin+Psychiatry.+1995%3b56%3a502.%0d%0a%0d%0a%0cDiscontinuation+of+Treatment+for+Anxiety+Disorders%0d%0a%e2%80%a2+Withdrawal%2frebound+more+common+with+Bzd+than+other+anxiolytic+treatment+%e2%80%a2+Relapse%3a+a+significant+problem+across+treatments.+Many+patients+require+maintenance+therapy+%e2%80%a2+Bzd+abuse+is+rare+in+non-predisposed+individuals+%e2%80%a2+Clinical+decision%3a+balance+comfort%2fcompliance%2f+comorbidity+during+maintenance+treatment+with+discontinuation-associated+difficulties%0d%0a%0d%0a%0cStrategies+for+Anxiolytic+Discontinuation%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+Slow+taper+Switch+to+longer-acting+agent+for+taper+Cognitive-Behavioral+therapy+Adjunctive%0d%0a%e2%80%93+Antidepressant+%e2%80%93+Anticonvulsant+%e2%80%93+%3fclonidine%2c+%3fbeta+blockers%2c+%3f+buspirone%0d%0a%0d%0a%0cSerotonin-Norepinephrine+Reuptake+Inhibitor%0d%0a%e2%80%a2+Venlafaxine-XR+(Effexor-XR)+75-300+mg%2fd%0d%0a%e2%80%93+Initiate+with+37.5+mg%2fd%0d%0a%0d%0a%e2%80%a2+Indicated+for+GAD%3b+effective+for+panic+disorder%2c+social+phobia%2c+PTSD%2c+OCD+%e2%80%a2+Typical+side+effects%0d%0a%e2%80%93+GI+distress%2c+jitteriness%2c+headaches%2c+sexual+disturbance%0d%0a%0d%0a%0cAtypical+Antidepressants%0d%0a%e2%80%a2+Nefazadone+(300-500+mg%2fd)+%e2%80%93+5-HT+reuptake+inhibitor+%e2%80%93+5-HT2+antagonist+%e2%80%93+Initiate+with+50+mg+bid+%e2%80%a2+Mirtazapine+%e2%80%93+Limited+experience+to+date+in+anxiety+disorders%0d%0a%0d%0a%0cAtypical+Antidepressants+(cont.)%0d%0a%e2%80%a2+Bupropion%0d%0a%e2%80%93+Based+on+limited+data%2c+considered+less+effective+for+panic+and+other+anxiety+disorders%2c+but+reports+suggestive+of+efficacy+for%0d%0a%e2%80%a2+panic+disorder+%e2%80%a2+social+anxiety+disorder+%e2%80%a2+PTSD%0d%0a%0d%0a%e2%80%a2+Trazodone%0d%0a%e2%80%93+Based+on+limited+data%2c+considered+less+effective+for+panic+and+other+anxiety+disorders%0d%0a%0d%0a%0cTricyclic+Antidepressants%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+Imipramine+(Tofranil)+Nortriptyline+(Pamelor)+Desipramine+(Norpramin)+Amitriptyline+(Elavil)+Doxepin+(Sinequan)%0d%0a%0d%0a%e2%80%a2+Effective+in+anxiety+with+or+without+comorbid+depression+%e2%80%a2+Recommended+dosage+2.25+mg%2fkg%2fd+Imipramine+or+its+equivalent+for+panic+%e2%80%a2+Initial+anxiety+worsening+(Initiate+with+%e2%80%9ctest%e2%80%9d+dose%2c+e.g.+10+mg%2fd+IMI)%0d%0a%0d%0a%0cTricyclic+Antidepressants+(cont)%0d%0a%e2%80%a2+Typical+TCA+side+effects+%e2%80%93+anticholinergic+effects+(dry+mouth%2c+blurred+vision%2c+constipation)+%e2%80%93+orthostatic+hypotension+%e2%80%93+cardiac+conduction+disturbance+%e2%80%93+weight+gain+%e2%80%93+sexual+dysfunction+%e2%80%a2+Lethal+in+overdose+%e2%80%a2+Weight+gain+and+sedation+often+become+increasingly+problematic+over+time+%e2%80%a2+Efficacy%3a+PDAG%2c+GAD%2c+PTSD%0d%0a%0d%0a%0cMonoamine+Oxidase+Inhibitors%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+Phenelzine+(Nardil)+45-90+mg%2fd+Tranylcypromine+(Parnate)+30-60+mg%2fd+Isocarboxacid+(Marplan)+10-30+mg%2fd+Initial+worsening+of+anxiety+is+unusual+Side+effects%3a+light-headedness%2c+neurological+symptoms%2c+weight+gain%2c+sexual+dysfunction%2c+edema+Dietary+restrictions%2fHypertensive+crisis%3b+%e2%80%9ccheese+reaction%e2%80%9d+Risk+of+lethal+overdose+and+toxicity+Generally+reserved+for+refractory+cases+Efficacy%3a+PDAG%2c+SP%2c+OCD%2c+PTSD%0d%0a%0d%0a%e2%80%a2%0d%0a%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2%0d%0a%0d%0a%0cBenzodiazepines%0d%0a%e2%80%a2+Potency+was+considered+critical+determinant+of+anti-panic+efficacy%0d%0a%e2%80%93+Alprazolam+(Xanax)+%e2%80%93+Clonazepam+(Klonopin)+%e2%80%93+%2b%2f-+Lorazepam+(Ativan)%0d%0a%0d%0a%e2%80%a2+But+comparable+doses+of+diazepam+as+effective+as+alprazolam+%e2%80%a2+All+benzodiazepines+effective+for+generalized+anxiety%0d%0a%0d%0a%0cPotential+Benefits+of+Benzodiazepine+Therapy%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+Effective+Short+latency+of+therapeutic+onset+Well+tolerated+Rapid+dose+adjustment+feasible+Can+be+used+%e2%80%9cprn%e2%80%9d+for+situational+anxiety%0d%0a%0d%0a%0cPotential+Drawbacks+of+Benzodiazepine+Therapy%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+Initial+sedation+Discontinuation+difficulties+Potential+for+abuse+in+substance+abusers+Not+effective+for+comorbid+depression%0d%0a%0d%0a%0cAlprazolam%0d%0a%e2%80%a2Effective+as+AD+in+panic+%e2%80%a2Advantages%3a+rapid+onset+of+effect%2c+lacks+typical+AD+side+effects+%e2%80%a2Disadvantages%3a+short+duration+of+effect+(i.e.%2c+multiple+dosing%2c+interdose+rebound)%2c+discontinuation+syndromes%2c+early+relapse%2c+abuse+potential%2c+disinhibition+%e2%80%a2Dosing%3a+anticipate+initial+sedation+(tachyphylaxis+usually+develops).+%e2%80%a2Range%3a+2-10+mg%2fd+(4-6+mg%2fd+usual)+(QID+dosing)%0d%0a%0d%0a%0cClonazepam%0d%0a%e2%80%a2+Labeled+as+anticonvulsant+%e2%80%a2+As+effective+as+alprazolam+for+panic%3b+issue+of+potency+for+antipanic+efficacy+%e2%80%a2+Advantages%3a+Pharmacokinetic%3a+longer+duration+of+effect+results+in+less+frequent+dosing%2c+interdose+symptoms%2c+early+relapse%2c+or+acute+withdrawal+symptoms.+Slower+onset+of+effect+diminishes+abuse+potential+%e2%80%a2+Disadvantages%3a+Depression+not+more+frequent+than+with+other+Bzd%e2%80%9ds%3b+disinhibition%2c+headaches+%e2%80%a2+Dosing%3a+anticipate+initial+sedation+(initiate+at+0.25-0.5+mg+qhs)+%e2%80%a2+Range%3a+1-5+mg%2fd+(BID+dosing)%0d%0a%0d%0a%0cCombining+Antidepressants+with+Benzodiazepines%0d%0a%e2%80%a2+Provides+rapid+anxiolysis+during+antidepressant+lag+%e2%80%a2+Decreases+early+anxiety+associated+with+initiation+of+antidepressant+%e2%80%a2+Treats+residual+anxiety+wtih+antidepressant+treatment+%e2%80%a2+Prevents+and+treats+depression+on+benzodiazepines%0d%0a%0d%0a%0cEnd-Point+(LVCF)+Analysis+of+Panic+Disorder+Severity+Scale+Scores+for+Each+Group%0d%0a2.5%0d%0a%e2%80%a0+*%0d%0aParoxetine+%2b+Placebo+Paroxetine+%2b+Clonazepam+Paroxetine+%2b+Clonazepame+w%2ftaper%0d%0a%0d%0a2%0d%0aAverage+PDSS+scores%0d%0a%0d%0a*%0d%0a%0d%0a1.5%0d%0a%0d%0a*+*%0d%0a%0d%0a1%0d%0a%0d%0a0.5%0d%0aClonazepam+Taper+Phase%0d%0a%0d%0a0%0d%0aWeek+00+Week+01+Week+02+Week+03+Week+04+Week+05+Week+06+Week+07+Week+08+Week+09+Week+10+Week+12%0d%0a%0d%0a*+Together+the+Clonazepam+groups+differ+from+the+Placebo+group+at+p%3c+.05+%e2%80%a0+Clonazepam+groups+differ+from+each+other+at+p%3c.05%0d%0a%0d%0aPollack%2c+et+al+2001%0d%0a%0d%0a%0cBuspirone%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+Non-benzodiazepine+anxiolytic+Non-sedating%2c+muscle+relaxant%2c+anticonvulsant+Effects+on+serotonin+and+dopamine+receptors+Indicated+for+GAD%3b+weak+antidepressant+effects+%e2%80%a2+Useful+as+SSRI+augmentation+for+panic%2c+social+phobia%2c+depression%2c+sexual+dysfunction+%e2%80%a2+Dosing%3a+30-60+mg%2fd%0d%0a%0d%0a%0cBeta+Blockers%0d%0a%e2%80%a2+Decrease+autonomic+arousal+%e2%80%a2+May+be+useful+as+adjunct+for+somatic+symptoms+of+panic+and+GAD+but+not+as+primary+treatment+%e2%80%a2+Useful+for+non-generalized+social+phobia%2c+performance+anxiety+subtype+%e2%80%a2+Propranolol+10-60+mg%2fd%3b+Atenolol+50-150+mg%2fd%0d%0a%0d%0a%0cAnticonvulsants%0d%0a%e2%80%a2+Valproate+and+gabapentin+effective+for+nonictal+panic+%e2%80%a2+Gabapentin+effective+for+social+phobia+%e2%80%a2+Gabapentin+(600-5400+mg%2fd)+used+as+alternative+to+benzodiazepine+%e2%80%a2+Valproate%2c+Carbamazepine%2c+Gabapentin%2c+Topiramate+and+Lamotrigine+for+PTSD%0d%0a%0d%0a%0cStrategies+for+Refractory+Anxiety+Disorder%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+Maximize+dose+Combine+antidepressant+and+benzodiazepine+Administer+cognitive-behavioral+therapy+Attend+to+psychosocial+issues%0d%0a%0d%0a.%0d%0a%0d%0a%0cStrategies+for+Refractory+Anxiety+Disorders%0d%0a%e2%80%a2+Augmentation%0d%0a%e2%80%93+Anticonvulsants%0d%0a%e2%80%a2+Gabapentin+%e2%80%a2+Valproate+%e2%80%a2+Topiramate%0d%0a%0d%0a%e2%80%a2+Combined+SSRI%2fTCA+%e2%80%a2+Alternative+antidepressant%0d%0a%e2%80%93+Clomipramine+%e2%80%93+MAOI%0d%0a%0d%0a%e2%80%93+%e2%80%93+%e2%80%93+%e2%80%93+%e2%80%93%0d%0a%0d%0aBeta+blocker+%e2%80%a2+Other+Buspirone+%e2%80%93+Inositol+Clonidine%2fGuanfacine+%e2%80%93+Kava-kava+Pindolol+%e2%80%93+Atypical+neuroleptics+Dopaminergic+agonists%0d%0a(e.g.%2c+Ropinirole)+for+social+phobia%0d%0a%0d%0a%e2%80%93+Cyproheptadine%0d%0a%0d%0a%0cCognitive-Behavioral+Therapy+for+Anxiety+Disorders%0d%0a%e2%80%a2+CBT+useful+alone+or+in+combination+with+medication+for%0d%0a%e2%80%93+Refractory+symptoms+%e2%80%93+Persistent+cognitive+factors%2c+behavioral+patterns+and+anxiety+sensitivity+%e2%80%93+Comorbid+conditions+%e2%80%93+Early+intervention+for+PTSD+prophylaxis%0d%0a%0d%0a%e2%80%a2+CBT+may+be+provided+by+therapist+or+selfadministered+(TherapyWorks+manuals+800-2280752%2f%2f%2fhttp%3a%2f%2fwww.psychcorp.com)%0d%0a%0d%0a%e2%80%a2+CBT+may+facilitate+medication+discontinuation%0d%0a.%0d%0a%0d%0a%0c%0cContinuation+Phase+Outcome+with+Sertraline+Treatment+of+PTSD+Based+on+Acute+Phase+Response+Category%0d%0aAcute+Phase+Responder+Status+Continuation+Phase+Responder+Status%0d%0a%0d%0aAcute+Phase+Responders%0d%0a%0d%0aSustained+Response%0d%0a8%25%0d%0a%0d%0a92%25%0d%0a%0d%0aLost+response%0d%0a%0d%0aAcute+Phase+Non-responders%0d%0a%0d%0aConverted+to+responder+54%25%0d%0aContinued+non-response%0d%0a46%25%0d%0a%0d%0a0%25%0d%0a%0d%0a20%25%0d%0a%0d%0a40%25%0d%0a%0d%0a60%25%0d%0a%0d%0a80%25%0d%0a%0d%0a100%25%0d%0a%0d%0aResponder+%3d+%3e+30%25+decrease+CAPS+and+CGI-S+%3d+1+or+2%0d%0aLondborg+et+al.+J+Clin+Psychiatry%2c+in+press.%0d%0a%0d%0a%0cLong-Term+Treatment+Of+GAD%0d%0a%e2%80%a2+Need+to+treat+long-term%0d%0a%e2%80%a2+Full+relapse+in+approximately+25%25+of+patients+1+month+after+stopping+treatment+%e2%80%a2+60%25-80%25+relapse+within+1st+year+after+stopping+treatment%0d%0aHales+et+al.+J+Clin+Psychiatry.+1997%3b58(suppl+3)%3a76.+Rickels+et+al.+J+Clin+Psychopharmacol.+1990%3b10(3+suppl)%3a101S.%0d%0a%0d%0a%0cEffect+Of+Venlafaxine+On+Total+HAM-A+Scores%0d%0a0+-2+-4+-6+Change+In+-8+Mean+HAM-A+Total+Score+-10+-12+-14+-16+-18+0+2+4+6+8+10+12+14+16+18+20+22+24+26+28+Week+Of+Treatment%0d%0aP%3c.001+for+venlafaxine+XR+vs+placebo+for+all+study+weeks+except+week+1+(.003)%2c+week+4+(.002)%2c+and+week+20+(.007)+Venlafaxine+XR+doses%3a+75+to+225+mg%2fd.+Gelenberg+et+al.+JAMA.+2000%3b283%3a3082.%0d%0a%0d%0aPlacebo+(N%3d123)+Venlafaxine+XR+(N%3d115)%0d%0a%0d%0a%0cParoxetine+Long-Term+GAD+Treatment+%25+Remission%0d%0aPhase+I%3a+Single-Blind+80+Paroxetine+20-50+mg+(N%3d599+responders)+Randomization+60+Patients+50+(%25)+40+30+20+10+0+1+Phase+II%3a+Double-Blind+Placebo+(N%3d274)+Paroxetine+(N%3d285)+*+*+*+*+*%0d%0a%0d%0a70%0d%0a%0d%0a*%0d%0a%0d%0a2%0d%0a%0d%0a3%0d%0a%0d%0a4%0d%0a%0d%0a6%0d%0a%0d%0a*+P%3c.01+vs+placebo.+Remission+%3d+HAM-A+%ef%82%a37%3b+LOCF+dataset.+GlaxoSmithKline+data+on+file%2c+2001.%0d%0a%0d%0a8+12+Week%0d%0a%0d%0a16%0d%0a%0d%0a20%0d%0a%0d%0a24%0d%0a%0d%0a28%0d%0a%0d%0a32%0d%0a%0d%0a%0cDiscontinuation+of+Treatment+for+Anxiety+Disorders%0d%0a%e2%80%a2+Withdrawal%2frebound+more+common+with+Bzd+than+other+anxiolytic+treatment+%e2%80%a2+Relapse%3a+a+significant+problem+across+treatments.+Many+patients+require+maintenance+therapy+%e2%80%a2+Bzd+abuse+is+rare+in+non-predisposed+individuals+%e2%80%a2+Clinical+decision%3a+balance+comfort%2fcompliance%2f+comorbidity+during+maintenance+treatment+with+discontinuation-associated+difficulties%0d%0a%0d%0a%0cStrategies+for+Anxiolytic+Discontinuation%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+Slow+taper+Switch+to+longer-acting+agent+for+taper+Cognitive-Behavioral+therapy+Adjunctive%0d%0a%e2%80%93+Antidepressant+%e2%80%93+Anticonvulsant+%e2%80%93+%3fclonidine%2c+%3fbeta+blockers%2c+%3f+buspirone%0d%0a%0d%0a%0c